Flagship Pioneering is merging three portfolio companies—Etaome, Cellarity, and Empress Therapeutics—into a new AI-aided drug discovery entity, Etcelera, aiming to improve prediction of how medicines perform in humans. The move reflects intensified investment in data-driven discovery and translation capabilities. The combined platform is positioned to compete directly in the crowded AI drug discovery space, where differentiation is increasingly tied to translational modeling and evidence generation speed rather than standalone model performance.